DuoTrav

DuoTrav Dosage/Direction for Use

travoprost + timolol

Manufacturer:

Novartis

Distributor:

DKSH
Full Prescribing Info
Dosage/Direction for Use
Dosage regimen: General target population: Adults: The recommended dosage of DuoTrav is one drop in the conjunctival sac of the affected eye(s) once daily in the morning or evening. It should be administered at the same time each day. The dosage of DuoTrav should not exceed one drop in the affected eye(s) once daily since it has been shown that more frequent administration of prostaglandin analogues may decrease the IOP-lowering effect.
If a dose is missed, treatment should continue with the next dose as planned. If more than one topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.
When substituting another ophthalmic antiglaucoma medicinal product with DuoTrav Eye Drops, Solution, the other medicinal product should be discontinued and DuoTrav Eye Drops, Solution should be started the following day.
Special populations: Hepatic and renal impairment: No studies have been conducted with DuoTrav or with timolol 5 mg/mL eye drops in patients with renal or hepatic impairment.
Travoprost alone has been studied in patients with mild to severe hepatic impairment and in patients with mild to severe renal impairment (creatinine clearance as low as 14 mL/min). No dose adjustment was necessary in these patients. Patients with hepatic or renal impairment are unlikely to a require dose adjustment with DuoTrav.
Pediatric patients (below 18 years): The use of DuoTrav in pediatric patients is currently not recommended. The safety and efficacy of the use of DuoTrav in children and adolescents below the age of 18 years have not been established. No data are available.
Geriatric patients (65 years of age and above): No overall differences in safety or effectiveness have been observed between elderly and other adult patients.
Method of administration: For ocular use only.
To avoid contamination, the dropper tip should not touch any surface. The dropper tip should also not come into contact with the eye as this may cause injury to the eye. When using nasolacrimal occlusion or closing the eyelids for 2 minutes, the systemic absorption is reduced. This may result in a decrease in systemic side effects and an increase in local activity.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in